The role of flumazenil in generalised anxiety disorder: a pilot naturalistic open-label study with a focus on treatment resistance.

Alexander T GalloStephen AddisVlad MartynHishani RamanathanGrace K WilkersonKellie S BennettSean D HoodHans StampferGary K Hulse

Published in: Therapeutic advances in psychopharmacology (2023)

This study presents preliminary results for subcutaneous continuous low-dose FMZ's effectiveness and safety in GAD. The findings suggest that it is a safe, well-tolerated, and feasible treatment option in this group of patients. Future randomised control trials are needed in this field to determine the efficacy of this treatment.

Keyphrases

low dose
open label
clinical trial
newly diagnosed
randomized controlled trial
end stage renal disease
squamous cell carcinoma
high dose
phase ii study
rectal cancer
current status
locally advanced